Table 1 Overview of mouse cohort and injection sites for GL261 tumor induction.

From: High-Resolution Ultrasound Data for AI-Based Segmentation in Mouse Brain Tumor

Mouse ID

Injection Location

In-Vivo/Ex-Vivo

Tumor/Non-Tumor

Tumor diameter

Gender

Weight

1

AP-0.3, ML-1.0, DV-2.3

Ex-Vivo

Tumor

5 mm

Female

?

2

AP-1.55, ML-1.6, DV-1.0

In-Vivo

Non-Tumor

—

Male

25.4 g

3

AP -1.55, ML-1.6, DV-1.0

In-Vivo

Non- Tumor

1.0 mm

Female

22.4 g

4

AP -1.55, ML-1.6, DV-1.0

In-Vivo

Tumor

4.0 mm

Female

21.2 g

5

AP -1.55, ML-1.6, DV-1.0

In-Vivo

Tumor

4.5 mm

Female

23.2 g

6

AP 0, ML -1.4, DV -1.8

In-Vivo

Tumor

3.2 mm

Female

20.9 g

7

AP 0, ML -1.4, DV -1.8

In-Vivo

Tumor

3.5 mm

Female

21.6 g

8

AP 0, ML -1.4, DV -1.8

In-Vivo

Tumor

4.5 mm

Female

22.2 g

9

AP 0, ML -1.4, DV -1.8

Ex-Vivo

Tumor

2.2 mm

Female

20.3 g

10

AP 0, ML -1.4, DV -1.8

In-Vivo

Non-Tumor

—

Female

23.9 g

11

AP 0, ML -1.4, DV -1.8

In-Vivo

Non-Tumor

—

Female

20.3 g

12

AP 0, ML -1.4, DV -1.8

In-Vivo

Non-Tumor

—

Female

21.05 g

  1. The anterior-posterior (AP), medial-lateral (ML), and dorsal-ventral (DV) positions are all relative to the standard skull reference point bregma.